| abstract |
(57) Abstract: The present invention can be represented by the general formula (I-1) (wherein, X is -O- or -CH 2 - and is; Y is -C (O) -, - ( CH 2) n - or -N (CH 3) - a and; n is either 1 or 2, or, X and Y are -CH = CH- together; Z is -NH -, - CH 2 -, - A 1 is a group (a) or (b); B is — (CH 2 ) m —; m is 0, 1 or 2; R 1 and R 2 Are each independently hydrogen or lower alkyl; R 3 is hydrogen or halogen; R 4 is hydrogen or hydroxy, and the dashed line is optionally a —CH 2 —CH 2 — group). A pharmaceutically acceptable acid addition salt of The compounds of the present invention are antagonists to the OFQ receptor. Thus, the treatment of memory and distraction, psychiatric, neurological and physiological disorders, including but not limited to anxiety and stress disorders, depression, Alzheimer's disease or other memory due to dementia It is useful in ameliorating metabolic disorders such as loss, epilepsy and seizures, symptoms of acute and / or chronic pain states, withdrawal symptoms of addictive drugs, regulation of water balance, Na + excretion, arterial blood pressure disorders and obesity. |